Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
JET (Satoshi Airline) Now Available to Trade on LBank Exchange
-
United Media Services Participates in Panel Discussion at the International Broadcasting Convention (IBC) in Amsterdam
-
AuMEGA Metals Extends Gold Mineralisation at Central Zone in Newfoundland
-
YTRanker Unveils Video Review Service to Build Rapid Social Proof on YouTube
-
World's 1st Flashlight Experience Store Kicks Off in Las Vegas
-
Master Roofing Inc. Strengthens Community Ties Through Local Engagement and Support
-
Eurasian Capital Announces Name Change to Eurasian Frontier Financial Capital to Propel Global Expansion Plans
-
Hero.io AI Innovations Take Center Stage at Token2049 Side Events
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk
-
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phas
-
ATA Celebrates America's Professional Truck Drivers During National Truck Driver Appreciation Week
-
Michael James of James Trial Law Proudly Accepts the Elite Lawyer Recognition for a Third Consecutive Years
-
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
-
Alcoa Announces Agreement to Sell its 25.1% Stake in Ma’aden Joint Venture to Ma’aden
-
Gold IRA Pros and Cons: Expert Explanation
-
Precious Metals IRA: Accounts, Reviews, and Rules Explained by an Expert
-
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
-
Scorpion Therapeutics Presents Initial Clinical Data From Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid
-
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
-
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Pro
-
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
-
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
-
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
-
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
-
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
-
Kleo Teams Up with Londis to Enhance Convenience Store Operations with Advanced EPOS and MPOS Solutions
-
Platform Science to Acquire Trimble's Global Transportation Telematics Business Units to Drive the Future of Transportation In-Cab Technology
-
Platform Science to Acquire Trimble’s Global Transportation Telematics Business Units to Drive the Future of Transportation In-Cab Technology
-
Rotev Wins Praise for Breakthrough Web Design Service Tailored to Deliver Results
-
KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions
-
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
-
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
-
Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024
-
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
-
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
-
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
-
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
-
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
-
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
-
Lewis Access Proudly Introduces its New Range of Premium Access Solutions - Made in the UK
-
XinKailian Biotechnology Unveils GMP-Certified Ubiquinol with Patent Safety, Set for Debut at Vitafoods Asia 2024
-
At Congressional Black Caucus Foundation's Phoenix Awards, President Biden And Vice President Harris Urge Caucus To Advance Their Vision For The Future Ahead Of The Presidential Election.
-
AHelp Launches Chrome Extension to Assist Users in Improving Academic Workflow with AI Tools
-
Uzbekistan Announces Global Speaker Lineup for 2024 World Conference on Creative Economy in Tashkent
-
MAX Power Mining Corp. Announces Results of Annual General and Special Meeting
-
The 3rd International Summit for Mayors of Rural Tourism Villages & the Forum of Best Tourism Villages is Coming to Huangling, Wuyuan
-
CNOOC Limited Successfully Withstands Super Typhoon "Yagi"
-
Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together
-
Exploring the Hidden Gems of Glendale's History Museum
-
Momcozy launches Brand Day Campaign and New Initiatives, Empowering Moms Through Cozy Evolution
